We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Investigation to Test the Efficacy of the High Flow (HF) Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea (OSA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01025440
First Posted: December 3, 2009
Last Update Posted: June 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Helios Klinik Ambrock
Information provided by (Responsible Party):
Fisher and Paykel Healthcare
December 1, 2009
December 3, 2009
June 19, 2017
November 2009
March 2010   (Final data collection date for primary outcome measure)
Efficacy to treat OSA [ Time Frame: Nights 3, 4 and 5 (after each PSG) ]
Not Provided
Complete list of historical versions of study NCT01025440 on ClinicalTrials.gov Archive Site
  • Sleep Quality [ Time Frame: Nights 3, 4 and 5 (after each PSG) ]
  • Participant Treatment Preference: HF-CPAP compared with CPAP [ Time Frame: Night 5 ]
Not Provided
Not Provided
Not Provided
 
An Investigation to Test the Efficacy of the High Flow (HF) Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea (OSA)
An Investigation to Test the Efficacy of a Novel CPAP Concept to Reduce the Apnea Hypopnea Index of Patients With Obstructive Sleep Apnea

Phase One:

High Flow (HF) CPAP (HF-CPAP) Titration:

Participants will attend the sleep lab to undergo a comprehensive split-night respiratory PSG. Each participant will be randomized to one of 20 L/min or 35 L/min of CPAP for the first half of the night and swapped to the alternate flow rate for the second half o the night.

At the completion of night 3 participants will be categorized as responders or non-responders. Only responders will continue to Phase 2 of the investigation.

Phase Two:

HF-CPAP compared with CPAP:

Participants will attend the sleep lab to undergo a comprehensive overnight respiratory PSG. Each participant will be randomized to HF-CPAP at a flow rate of 35 L/min or to conventional CPAP at their therapeutic pressure. They will spend the entire night on this treatment arm. Thew following night participants will undergo the alternative treatment arm for the duration of the night.

Each patient will complete a clinical consultation followed by admission to the HELIOS Klinik Hagen-Ambrock facility to undergo routine assessment, diagnosis and CPAP titration (if necessary) of OSA. This will be performed according to the routine clinical care procedures and protocols of the site. The eligibility of each participant will be established during these routine clinical care nights. After night 2 eligible participants will be offered participation in the investigation.

Phase One:

Night 1 (Routine Clinical Care) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive overnight diagnostic PSG, in order to establish the existence and severity of OSA. If the participant has

  1. a positive diagnosis of OSA with an AHI > 15 events/hr and
  2. ≥ 90% of all events are Hypopneas they will be eligible to progress to Night 3. Night 2 (Routine Clinical Care) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a standard CPAP titration, in order to determine their therapeutic CPAP pressure. At this stage, if the participant is eligible, they will be offered participation in the investigation. If potential participants are ineligible or unwilling to participate, they will continue along the routine clinical care path.

Night 3 (Flow Titration) Consented participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive split-night respiratory PSG.

Each participant will be randomized to one of 20 L/min or 35 L/min of HF-CPAP for the first half of the night. A minimum of three hours on this flow must be recorded on the PSG before participants can be swapped to the alternate flow. Three hours on the alternate flow is also required for this half of the night to be deemed successful.

Responder/Non-responder Determination At the completion of night 3 participants will be categorized as responders or non-responders.

Only responders will continue to Phase 2 of the investigation. A responder is someone who;

  1. Achieves a > 50% reduction in AHI and
  2. Achieves an RDI < 10 events/hr. Investigation Break Before responders progress to Phase Two participants will be sent home for 1 week. During this time they will be instructed to undertake CPAP treatment. Their CPAP device will be set to their therapeutic pressure which was determined on Night 2.

Phase Two:

Night 4 (HF-CPAP compared with CPAP) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive overnight respiratory PSG.

Each participant will be randomized to OpenCPAP at a flow rate of 35 L/min or to conventional CPAP at their therapeutic pressure. They will spend the entire night on this treatment arm.

Night 5 (HF-CPAP compared with CPAP) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive overnight respiratory PSG.

Participants will be swapped to the alternative treatment arm, either HF-CPAP at a flow rate of 35 L/min or to conventional CPAP at their therapeutic pressure. They will spend the entire night on this treatment. In the morning at completion of the PSG, participants will be asked which treatment Night (4 or 5) they preferred.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Obstructive Sleep Apnea
Device: Continuous Positive Airway Pressure

Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.

Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)

Duration:

Other Name: Positive airway pressure
  • Active Comparator: CPAP

    Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.

    Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.

    Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)

    Intervention: Device: Continuous Positive Airway Pressure
  • Active Comparator: HFCPAP

    Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.

    Dose: During HF CPAP 35 L/min wil be administered.

    Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)

    Intervention: Device: Continuous Positive Airway Pressure
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
May 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged ≥ 18 years.
  • AHI > 15 events per hour and ≥ 90% of events must be Hypopneas.

Exclusion Criteria:

  • Any medical condition which contraindicates the use of CPAP or AutoCPAP. See Appendix D for this list.
  • Requires supplemental oxygen.
  • Unstable cardiovascular disease (untreated or resistant hypertension acceptable).
  • Unstable psychiatric disease.
  • Other significant sleep disorder.
  • Inability to tolerate CPAP due to nasal obstruction or claustrophobia, as determined by the investigation investigator.
  • Any known factor or disease that might interfere with treatment compliance, investigation conduct or interpretation of the results such as psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with investigational requirements.
  • Participation in another clinical investigation in the previous month.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01025440
FPHC LP-CPAP09-01
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Plan to Share IPD: Undecided
Fisher and Paykel Healthcare
Fisher and Paykel Healthcare
Helios Klinik Ambrock
Principal Investigator: George Nilius, M.D HELIOS-Klinik Hagen Ambrock
Fisher and Paykel Healthcare
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP